News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
687,325 Results
Type
Article (39127)
Company Profile (282)
Press Release (647916)
Section
Business (203895)
Career Advice (1994)
Deals (35369)
Drug Delivery (89)
Drug Development (80842)
Employer Resources (168)
FDA (16097)
Job Trends (14806)
News (344622)
Policy (32450)
Tag
Academia (2530)
Alliances (49156)
Alzheimer's disease (1250)
Approvals (16033)
Artificial intelligence (143)
Bankruptcy (352)
Best Places to Work (11569)
Biotechnology (201)
Breast cancer (186)
Cancer (1323)
Cardiovascular disease (106)
Career advice (1662)
Cell therapy (269)
Clinical research (64591)
Collaboration (442)
Compensation (245)
COVID-19 (2540)
C-suite (106)
Data (1358)
Diabetes (163)
Diagnostics (6166)
Earnings (84872)
Employer resources (146)
Events (109926)
Executive appointments (364)
FDA (16726)
Funding (408)
Gene therapy (192)
GLP-1 (590)
Government (4331)
Healthcare (18684)
Infectious disease (2629)
Inflammatory bowel disease (110)
Interviews (309)
IPO (16328)
Job creations (3625)
Job search strategy (1418)
Layoffs (416)
Legal (7859)
Lung cancer (186)
Manufacturing (194)
Medical device (13205)
Medtech (13210)
Mergers & acquisitions (19172)
Metabolic disorders (431)
Neuroscience (1561)
NextGen Class of 2024 (6501)
Non-profit (4466)
Northern California (1638)
Obesity (250)
Opinion (180)
Patents (114)
People (56400)
Phase I (20086)
Phase II (28444)
Phase III (21211)
Pipeline (503)
Postmarket research (2560)
Preclinical (8541)
Radiopharmaceuticals (236)
Rare diseases (252)
Real estate (5890)
Regulatory (21624)
Research institute (2309)
Resumes & cover letters (349)
Southern California (1422)
Startups (3563)
United States (14734)
Vaccines (560)
Weight loss (175)
Date
Last 7 days (678)
Last 30 days (2338)
Last 365 days (35223)
2024 (34425)
2023 (40076)
2022 (51173)
2021 (55714)
2020 (54087)
2019 (46542)
2018 (35019)
2017 (32110)
2016 (31481)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (194)
Asia (37228)
Australia (6077)
California (3682)
Canada (1409)
China (290)
Colorado (167)
Connecticut (170)
Europe (79734)
Florida (513)
Georgia (130)
Illinois (372)
Indiana (218)
Kansas (96)
Maryland (614)
Massachusetts (2880)
Michigan (169)
Minnesota (285)
New Jersey (1062)
New York (1047)
North Carolina (732)
Northern California (1638)
Ohio (144)
Pennsylvania (901)
South America (1091)
Southern California (1422)
Texas (530)
Utah (105)
Washington State (391)
687,325 Results for "lyndra inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Lyndra Therapeutics Raises $101 Million in Series E Funding
Lyndra Therapeutics today announced the closing of a $101 million Series E financing round.
December 21, 2023
·
4 min read
Drug Development
Phase III Schizophrenia Trial Shows Lyndra’s Weekly Risperidone ‘Comparable’ to J&J’s Daily Risperdal
The late-stage pharmacokinetic study was stopped early due to efficacy at interim analysis, Lyndra Therapeutics said Thursday. A six-month safety study will start in the second half of 2024.
January 4, 2024
·
1 min read
·
Kate Goodwin
Drug Development
Lyndra Therapeutics Announces Positive Data from Pivotal Phase 3 Study with Oral Weekly Risperidone (LYN-005) for Schizophrenia
Lyndra Therapeutics today announced positive data from the STARLYNG-1 (LYN-005-C-301) study, comparing the pharmacokinetic (PK) profile of oral weekly risperidone (LYN-005) with immediate-release Risperdal administered daily to adults living with schizophrenia and schizoaffective disorder.
January 4, 2024
·
4 min read
Business
Lyndra Therapeutics Announces Leadership Changes, Update on Pivotal Trial Progress
Lyndra Therapeutics today announced long-time Lyndra executive President and Chief Operations Officer Jessica Ballinger has been appointed President and CEO.
July 17, 2023
·
6 min read
Business
Lyndra Therapeutics Announces New Board Members and Chief Technology Officer
Lyndra Therapeutics announced the appointment of Kyle B. Haraldsen as Lyndra’s Chief Technology Officer and Helene Madonick, J.D., former Deputy General Counsel and Interim Director, Gender Equality Program Strategy at the Bill & Melinda Gates Foundation, and Ashish Singh, MBA, Senior Partner and former Healthcare Global Practice Leader at Bain & Company, to Lyndra’s Board of Directors.
January 5, 2023
·
5 min read
Genetown
Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective Disorder
Lyndra Therapeutics, a clinical-stage biopharmaceutical company working to make daily pills a thing of the past, today announced it has dosed the first participant in its pivotal clinical trial investigating oral weekly risperidone (LYN-005).
May 9, 2023
·
7 min read
Genetown
Lyndra Therapeutics Presents Data on Long-Acting Oral Weekly Risperidone (LYN-005) at American Society of Clinical Psychopharmacology 2023 Annual Conference
Lyndra Therapeutics, a clinical-stage biopharmaceutical company working to make daily pills a thing of the past, today announced it will present a poster on the results of a simulation-based predictive modeling study comparing the Positive and Negative Syndrome Scale (PANSS) scores produced by oral weekly risperidone (LYN-005) and oral daily risperidone at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting.
May 31, 2023
·
6 min read
Genetown
Lyndra Therapeutics’ LYNX™ Drug Delivery Platform Wins 2022 Fierce Life Sciences Innovation Award for Drug Delivery Technology
Lyndra Therapeutics today announced that its LYNX™ drug delivery platform was named the winner of the Fierce Life Sciences Innovation Awards 2022 award in the Drug Delivery Technology category.
November 15, 2022
·
3 min read
Business
Lyndra Therapeutics Advances Leadership in Key Roles
Lyndra Therapeutics today announced the appointment of two new members of its Board of Directors: Doug Dachille, former Chief Investment Officer of American International Group, Inc.
September 20, 2021
·
4 min read
Business
Lyndra Therapeutics Appoints Klas Holmlund, CFA, as Chief Financial Officer
Lyndra Therapeutics today announced the appointment of Klas Holmlund, CFA, as Chief Financial Officer.
December 8, 2021
·
4 min read
1 of 68,733
Next